drugset
drugset / Trial / NCT01849250

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

NCT01849250 ↗

Phase 2 Completed 65 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupDouble-blindPrevention

Summary

This randomized phase II trial studies how well docosahexaenoic acid works in preventing recurrence in breast cancer survivors. Docosahexaenoic acid supplement may prevent recurrence in breast cancer survivors.

Timeline

Start
2013-05
Primary completion
2016-01-11
Completion
2020-04-22

Drugs

EvaluationDrugModalityDoseRoute
Subject DOCONEXENT Other / unclassified 1000 mg Oral

Indications

breast benign neoplasm ductal breast carcinoma in situ invasive breast carcinoma lobular breast carcinoma in situ mammary Paget disease